2023 Pain Management Symposium Enduring Material

This enduring material has been approved by KBML as meeting the statutory requirements of HB1 and the Consolidated Appropriations Act (MATE)

Learn now and fulfill your state-mandated Continuing Medical Education (CME) credits.

This activity has been approved by:

Kentucky Medical Association for a maximum of 8 AMA PRA Category 1 Credits™

Kentucky Board of Medical Licensure for a maximum of 8 AMA PRA Category 1 Credits™ – meeting the mandatory CME requirements for HB1/MATE Act/Prescribing Controlled Substances

Kentucky Board of Nursing for up to 8 CEUs

Kentucky Board of Respiratory Care for up to 8 CEU hours

Kentucky Board of Pharmacy for up to 8 CEU hours

Kentucky Board of Imaging & Radiation Therapy for up to 8 CEU hours

Kentucky Physical Therapy Association for up to 8 contact hours

Release Date: October 16, 2023

Expiration Date: October 16, 2026

(Please note that credit will no longer be issued for this activity after this date)

Media Type: Internet Enduring Material Activity / Live Lecture Video

Completion Time: 8.00 hours

Registration Fee: FREE

Target Audience:

This symposium is designed to meet the educational needs of physicians, physician assistants, nurse practitioners, family practitioners, medical students, nurses, and all other allied health professionals caring for pain management patients.

Speakers:

Danesh Mazloomdoost, MD
Martika Martin, PharmD, MBA, BCGP, RPh
Dana Quesinberry, JD, DrPH
Alexander Bautista, MD, MBA, FASA
Eloise Fields, DO
Chris Delcher, PhD
Michael E. Harned, MD

Learning Objectives:

At the completion of this program, the participant will be able to:

Discuss the pathophysiology of chronic pain and impact of opioids
Define the joint degenerative process
Identify the framework to treat pain sustainably without opioids
Summarize the neuropath physiology of pain and addiction
Summarize the pharmacology of buprenorphine
Identify formulations of buprenorphine
Examine the role of buprenorphine in the treatment of opioid use disorder
Discuss FDA approved dosing of buprenorphine for opioid use disorder
Explain micro-induction of buprenorphine & its place in therapy for treatment of opioid use disorder
Describe federal and state regulations related to the prescribing of buprenorphine
Define the role of fentanyl and analogs in fatal and nonfatal overdoses in Kentucky
Assess the value of public health surveillance of drug overdose to tertiary care decision making
Integrate surveillance data into current clinical decision-making support tools
Differentiate drug involvement in overdoses by geography, biological sex, race/ethnicity, and age
Assess the impact of the opioid cases
Describe the importance of patient assessment before initiating opioid therapy
Discuss alternative treatment options
Utilize guidance on initiating opioid therapy
Review the importance of ongoing monitoring and follow-up
Examine the 3 FDA approved medications for opioid use disorder
Review basic concepts surrounding treatment of withdrawal and pain in patients with opioid use disorder and how they relate
Develop strategies for managing pain in patients with OUD and recognize how MOUD alters pain management
Review all relevant updates to KASPER that may affect clinical practice
Explain the role of KASPER and PDMPs in population-based research on controlled substances
Identify trends in epidemiology and licit and illicit drug use in Kentucky and beyond
Explain what interventional pain medicine can now offer in patients with spinal pain
Recognize when to refer patients for advanced pain procedures
Describe pharmacological properties, mechanism of action & indications for use in opioid use disorder
Discuss preoperative assessment & management of buprenorphine and methadone during preoperative period
Discuss strategies and existing guidelines and recommendations and the importance of multidisciplinary collaboration in patients on buprenorphine and methadone for OUD

Instructions for Participation and Credit:

To receive credit you are required to:

Review video content,
Complete the activity quiz
Submit the CME/CE registration and evaluation.

After completion of the activity, a certificate will be sent to you via your preferred retrieval method as listed on the evaluation. If you have questions about the participation process, please e-mail CME@pikevillehospital.org or call (606) 430-8110

Accreditation & Designation Statement

Physicians

Accreditation: Pikeville Medical Center is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.

Designation: Pikeville Medical Center designates this internet enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in the activity.

Disclaimer

The opinions and recommendations expressed by faculty and other experts, whose input is included in this activity, are their own and do not represent Pikeville Medical Center endorsement. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacological therapy to patients.

Special Needs Statement

If you have special needs, please contact our office and we will do our best to accommodate you.

Disclosure of Relevant Financial Relationships
It is the policy of Pikeville Medical Center to adhere to ACCME Criteria, Policies, and Standards for Integrity and Independence in Accredited Continuing Education in order to ensure fair balance, independence, objectivity, and scientific rigor in all its accredited activities. All faculty and planners, along with the Activity Director and Co-Director, participating in accredited activities are expected to disclose relevant financial relationships pertaining to their contribution to the activity. Relationship information is analyzed to determine whether conflicts of interest exist. All conflicts of interest are mitigated prior to participation in the planning or implementation of this activity.

Faculty members are also expected to disclose any discussion of (1) off label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States. All disclosures will be made at the time of this accredited continuing education activity.

The following Course Faculty and Planning Committee have reported having no relevant financial relationships with any ineligible company related to the content of this educational activity.

Course Faculty:

John Blackburn, MD
Danesh Mazloomdoost, MD
Martika Martin, PharmD, MBA, BCGP, RPh
Dana Quesinberry, JD, DrPH
Alexander Bautista, MD, MBA, FASA
Eloise Fields, DO
Michael E. Harned, MD

Planning Committee:

Brenda Adams, CCMEC, Director Continuing Medical Educatiom
Melissa Bowles, Medical Education Coordinator
Michelle Caudill, BSN, RN, Staff Development Specialist